A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
|Videos|January 10, 2018
Examining Response Rates in MSI-H and NTRK Fusion GI Cancers
Author(s)Luis A. Diaz, M.D.
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Advertisement
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Finding these biomarkers in patients with GI cancers can be particularly important, as it can help choose a treatment plan that can have a dramatic response in this group of patients.
Advertisement
Related to this article
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
Advertisement
Advertisement
Trending on CURE
1
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
2
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
3
Urologic Oncologist Answers Top Searched Questions in Bladder Cancer
4
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
5